Eli Lilly announced Tuesday that its diabetes and weight loss drug tirzepatide succeeded in a Phase II study for MASH, or metabolic dysfunction-associated steatohepatitis.
Lei Lei Wu is a news reporter for Endpoints News, specializing in reporting on drugs and biotechs. With a focus on the pharmaceutical industry, Lei Lei covers topics such as clinical trial results, FDA approvals, and biotech company developments.